CA2445763A1

CA2445763A1 - Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions

Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions Download PDF

Info

Publication number: CA2445763A1
Authority: CA; Canada
Prior art keywords: composition; microtubule agent; carrier; polysaccharide; polypeptide
Prior art date: 2001-05-01
Legal status : Abandoned

Application number

CA002445763A

Other languages

English (en)

French (fr)

Inventor

David M. Gravett

Richard Liggins

Philip M. Toleikis

William Hunter

Current Assignee

Angiotech Pharmaceuticals Inc

Original Assignee

Individual

Priority date

2001-05-01

Filing date

2002-05-01

Publication date

2002-11-07

2002-05-01 Application filed by Individual filed Critical Individual

2002-11-07 Publication of CA2445763A1 publication Critical patent/CA2445763A1/en

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 301
229940044684 anti-microtubule agent Drugs 0.000 title claims abstract description 214
239000005017 polysaccharide Substances 0.000 title claims abstract description 127
229920001282 polysaccharide Polymers 0.000 title claims abstract description 117
150000004676 glycans Chemical class 0.000 title claims abstract description 29
230000004968 inflammatory condition Effects 0.000 title claims abstract description 18
108090000765 processed proteins & peptides Proteins 0.000 title claims description 102
102000004196 processed proteins & peptides Human genes 0.000 title claims description 99
229920001184 polypeptide Polymers 0.000 title claims description 95
239000003814 drug Substances 0.000 title description 52
238000011282 treatment Methods 0.000 title description 35
238000002360 preparation method Methods 0.000 title description 17
238000000034 method Methods 0.000 claims abstract description 146
206010028980 Neoplasm Diseases 0.000 claims abstract description 67
239000000693 micelle Substances 0.000 claims abstract description 62
206010003246 arthritis Diseases 0.000 claims abstract description 27
230000000893 fibroproliferative effect Effects 0.000 claims abstract description 24
230000002757 inflammatory effect Effects 0.000 claims abstract description 21
239000002502 liposome Substances 0.000 claims abstract description 16
229930012538 Paclitaxel Natural products 0.000 claims description 199
229960001592 paclitaxel Drugs 0.000 claims description 199
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 198
229920002674 hyaluronan Polymers 0.000 claims description 134
229960003160 hyaluronic acid Drugs 0.000 claims description 132
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 108
230000008569 process Effects 0.000 claims description 64
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
239000006184 cosolvent Substances 0.000 claims description 50
239000000243 solution Substances 0.000 claims description 50
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 48
239000000499 gel Substances 0.000 claims description 47
229940123237 Taxane Drugs 0.000 claims description 46
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
239000000017 hydrogel Substances 0.000 claims description 44
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 42
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 38
229920001661 Chitosan Polymers 0.000 claims description 34
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 32
239000007921 spray Substances 0.000 claims description 32
239000002105 nanoparticle Substances 0.000 claims description 26
229920002678 cellulose Chemical class 0.000 claims description 24
239000001913 cellulose Chemical class 0.000 claims description 24
235000010980 cellulose Nutrition 0.000 claims description 24
239000012736 aqueous medium Substances 0.000 claims description 23
229960001338 colchicine Drugs 0.000 claims description 21
229940122803 Vinca alkaloid Drugs 0.000 claims description 19
239000012071 phase Substances 0.000 claims description 19
239000004721 Polyphenylene oxide Substances 0.000 claims description 18
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 18
239000000839 emulsion Substances 0.000 claims description 18
230000002209 hydrophobic effect Effects 0.000 claims description 18
229920000570 polyether Polymers 0.000 claims description 18
239000004094 surface-active agent Substances 0.000 claims description 18
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 17
238000001914 filtration Methods 0.000 claims description 17
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
229920001400 block copolymer Polymers 0.000 claims description 16
235000011187 glycerol Nutrition 0.000 claims description 16
238000007912 intraperitoneal administration Methods 0.000 claims description 14
239000004530 micro-emulsion Substances 0.000 claims description 14
108010088751 Albumins Proteins 0.000 claims description 13
102000009027 Albumins Human genes 0.000 claims description 13
102000009123 Fibrin Human genes 0.000 claims description 13
108010073385 Fibrin Proteins 0.000 claims description 13
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 13
229950003499 fibrin Drugs 0.000 claims description 13
AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 claims description 12
AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
239000002088 nanocapsule Substances 0.000 claims description 12
239000002077 nanosphere Substances 0.000 claims description 12
108010035532 Collagen Proteins 0.000 claims description 11
102000008186 Collagen Human genes 0.000 claims description 11
241000124008 Mammalia Species 0.000 claims description 11
229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 11
229920001436 collagen Polymers 0.000 claims description 11
239000007788 liquid Substances 0.000 claims description 11
229920001231 Polysaccharide peptide Polymers 0.000 claims description 10
239000006071 cream Substances 0.000 claims description 10
239000002674 ointment Substances 0.000 claims description 10
108010022457 polysaccharide peptide Proteins 0.000 claims description 10
229920002307 Dextran Polymers 0.000 claims description 9
108010010803 Gelatin Proteins 0.000 claims description 9
229920001577 copolymer Polymers 0.000 claims description 9
229920000159 gelatin Polymers 0.000 claims description 9
239000008273 gelatin Substances 0.000 claims description 9
235000019322 gelatine Nutrition 0.000 claims description 9
235000011852 gelatine desserts Nutrition 0.000 claims description 9
239000004005 microsphere Substances 0.000 claims description 9
239000007864 aqueous solution Substances 0.000 claims description 8
229920001519 homopolymer Polymers 0.000 claims description 8
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 8
230000005855 radiation Effects 0.000 claims description 8
239000011780 sodium chloride Substances 0.000 claims description 8
229920000858 Cyclodextrin Polymers 0.000 claims description 7
230000001954 sterilising effect Effects 0.000 claims description 7
208000035346 Margins of Excision Diseases 0.000 claims description 6
229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 6
UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims description 6
229920000469 amphiphilic block copolymer Polymers 0.000 claims description 6
239000008346 aqueous phase Substances 0.000 claims description 6
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 6
229920000728 polyester Polymers 0.000 claims description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
229940068968 polysorbate 80 Drugs 0.000 claims description 6
229920000053 polysorbate 80 Polymers 0.000 claims description 6
239000000843 powder Substances 0.000 claims description 6
230000000699 topical effect Effects 0.000 claims description 6
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 5
HDTIFOGXOGLRCB-VVGYGEMISA-N 2-[2-[(2r,3r)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCC(OCCO)[C@H]1OCC(OCCO)[C@H]1OCCO HDTIFOGXOGLRCB-VVGYGEMISA-N 0.000 claims description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
150000002772 monosaccharides Chemical class 0.000 claims description 4
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
235000019485 Safflower oil Nutrition 0.000 claims description 3
229960002903 benzyl benzoate Drugs 0.000 claims description 3
239000002285 corn oil Substances 0.000 claims description 3
235000005687 corn oil Nutrition 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
150000002016 disaccharides Chemical class 0.000 claims description 3
239000001087 glyceryl triacetate Substances 0.000 claims description 3
235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
239000003813 safflower oil Substances 0.000 claims description 3
235000005713 safflower oil Nutrition 0.000 claims description 3
229960002622 triacetin Drugs 0.000 claims description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
229920005682 EO-PO block copolymer Polymers 0.000 claims description 2
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 claims description 2
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 2
235000012000 cholesterol Nutrition 0.000 claims description 2
235000010445 lecithin Nutrition 0.000 claims description 2
239000000787 lecithin Substances 0.000 claims description 2
229940067606 lecithin Drugs 0.000 claims description 2
235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 2
239000001570 sorbitan monopalmitate Substances 0.000 claims description 2
229940031953 sorbitan monopalmitate Drugs 0.000 claims description 2
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims description 2
229940117972 triolein Drugs 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 33
201000010099 disease Diseases 0.000 abstract description 31
102000004169 proteins and genes Human genes 0.000 abstract description 20
108090000623 proteins and genes Proteins 0.000 abstract description 20
150000004804 polysaccharides Chemical class 0.000 description 100
238000001356 surgical procedure Methods 0.000 description 57
239000007943 implant Substances 0.000 description 48
-1 poly(L-glutamic acid) Polymers 0.000 description 42
229940079593 drug Drugs 0.000 description 41
238000002347 injection Methods 0.000 description 37
239000007924 injection Substances 0.000 description 37
229920000642 polymer Polymers 0.000 description 33
230000002829 reductive effect Effects 0.000 description 28
230000004054 inflammatory process Effects 0.000 description 27
206010061218 Inflammation Diseases 0.000 description 26
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 25
210000001519 tissue Anatomy 0.000 description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
230000001946 anti-microtubular Effects 0.000 description 24
230000037390 scarring Effects 0.000 description 23
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
230000015572 biosynthetic process Effects 0.000 description 21
239000012530 fluid Substances 0.000 description 21
238000009472 formulation Methods 0.000 description 21
208000010412 Glaucoma Diseases 0.000 description 20
239000006072 paste Substances 0.000 description 20
238000002271 resection Methods 0.000 description 20
229960003668 docetaxel Drugs 0.000 description 19
230000001225 therapeutic effect Effects 0.000 description 19
239000003795 chemical substances by application Substances 0.000 description 18
230000006378 damage Effects 0.000 description 17
238000007726 management method Methods 0.000 description 17
238000013270 controlled release Methods 0.000 description 16
238000003756 stirring Methods 0.000 description 16
210000004087 cornea Anatomy 0.000 description 15
229960002110 vincristine sulfate Drugs 0.000 description 15
AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 15
208000031737 Tissue Adhesions Diseases 0.000 description 14
201000011510 cancer Diseases 0.000 description 14
229910052739 hydrogen Inorganic materials 0.000 description 14
238000002560 therapeutic procedure Methods 0.000 description 14
229960004982 vinblastine sulfate Drugs 0.000 description 14
KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 14
208000002177 Cataract Diseases 0.000 description 13
210000001015 abdomen Anatomy 0.000 description 13
239000001257 hydrogen Substances 0.000 description 13
206010039073 rheumatoid arthritis Diseases 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
230000000694 effects Effects 0.000 description 12
238000005538 encapsulation Methods 0.000 description 12
150000002148 esters Chemical class 0.000 description 12
239000000463 material Substances 0.000 description 12
229910052760 oxygen Inorganic materials 0.000 description 11
229960003048 vinblastine Drugs 0.000 description 11
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 11
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
239000000969 carrier Substances 0.000 description 10
208000030533 eye disease Diseases 0.000 description 10
208000027866 inflammatory disease Diseases 0.000 description 10
239000001301 oxygen Substances 0.000 description 10
210000001525 retina Anatomy 0.000 description 10
230000008961 swelling Effects 0.000 description 10
238000012360 testing method Methods 0.000 description 10
230000002792 vascular Effects 0.000 description 10
229960004528 vincristine Drugs 0.000 description 10
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 10
208000027418 Wounds and injury Diseases 0.000 description 9
125000000217 alkyl group Chemical group 0.000 description 9
210000004204 blood vessel Anatomy 0.000 description 9
210000000481 breast Anatomy 0.000 description 9
230000007423 decrease Effects 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
210000003127 knee Anatomy 0.000 description 9
TYLVGQKNNUHXIP-MHHARFCSSA-N 10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 TYLVGQKNNUHXIP-MHHARFCSSA-N 0.000 description 8
206010055665 Corneal neovascularisation Diseases 0.000 description 8
206010012689 Diabetic retinopathy Diseases 0.000 description 8
230000001684 chronic effect Effects 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
201000000159 corneal neovascularization Diseases 0.000 description 8
239000006185 dispersion Substances 0.000 description 8
230000006870 function Effects 0.000 description 8
150000002431 hydrogen Chemical class 0.000 description 8
231100000682 maximum tolerated dose Toxicity 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
230000004044 response Effects 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 8
208000002193 Pain Diseases 0.000 description 7
241000700159 Rattus Species 0.000 description 7
210000000683 abdominal cavity Anatomy 0.000 description 7
230000003187 abdominal effect Effects 0.000 description 7
238000005299 abrasion Methods 0.000 description 7
210000000845 cartilage Anatomy 0.000 description 7
210000004534 cecum Anatomy 0.000 description 7
208000014674 injury Diseases 0.000 description 7
201000003142 neovascular glaucoma Diseases 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
201000008482 osteoarthritis Diseases 0.000 description 7
230000036407 pain Effects 0.000 description 7
239000002904 solvent Substances 0.000 description 7
238000004659 sterilization and disinfection Methods 0.000 description 7
YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 6
241000252983 Caecum Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241001111421 Pannus Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
210000002159 anterior chamber Anatomy 0.000 description 6
125000001589 carboacyl group Chemical group 0.000 description 6
238000012377 drug delivery Methods 0.000 description 6
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
239000001863 hydroxypropyl cellulose Substances 0.000 description 6
229940071676 hydroxypropylcellulose Drugs 0.000 description 6
210000001503 joint Anatomy 0.000 description 6
239000003755 preservative agent Substances 0.000 description 6
230000002265 prevention Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
201000004595 synovitis Diseases 0.000 description 6
230000000007 visual effect Effects 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
208000008822 Ankylosis Diseases 0.000 description 5
208000032843 Hemorrhage Diseases 0.000 description 5
206010023198 Joint ankylosis Diseases 0.000 description 5
206010052904 Musculoskeletal stiffness Diseases 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
230000008901 benefit Effects 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
230000003902 lesion Effects 0.000 description 5
210000003141 lower extremity Anatomy 0.000 description 5
230000036210 malignancy Effects 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
210000000713 mesentery Anatomy 0.000 description 5
239000002245 particle Substances 0.000 description 5
230000001575 pathological effect Effects 0.000 description 5
229920001308 poly(aminoacid) Polymers 0.000 description 5
239000000047 product Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
210000002437 synoviocyte Anatomy 0.000 description 5
150000004579 taxol derivatives Chemical class 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
210000000115 thoracic cavity Anatomy 0.000 description 5
206010002091 Anaesthesia Diseases 0.000 description 4
201000004569 Blindness Diseases 0.000 description 4
208000003174 Brain Neoplasms Diseases 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
208000009386 Experimental Arthritis Diseases 0.000 description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
206010023215 Joint effusion Diseases 0.000 description 4
206010023232 Joint swelling Diseases 0.000 description 4
102000029749 Microtubule Human genes 0.000 description 4
108091022875 Microtubule Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
241000219061 Rheum Species 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
241000202349 Taxus brevifolia Species 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
125000004423 acyloxy group Chemical group 0.000 description 4
230000037005 anaesthesia Effects 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000012876 carrier material Substances 0.000 description 4
208000037976 chronic inflammation Diseases 0.000 description 4
230000006020 chronic inflammation Effects 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
230000003628 erosive effect Effects 0.000 description 4
LOSVFNDAEKTRMV-UHFFFAOYSA-N ethyl n-[5-amino-3-(4-methylphenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate Chemical compound N=1C=2C(N)=NC(NC(=O)OCC)=CC=2NCC=1C1=CC=C(C)C=C1 LOSVFNDAEKTRMV-UHFFFAOYSA-N 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000001497 fibrovascular Effects 0.000 description 4
235000013305 food Nutrition 0.000 description 4
239000007789 gas Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
229960003132 halothane Drugs 0.000 description 4
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 4
229940072322 hylan Drugs 0.000 description 4
210000000629 knee joint Anatomy 0.000 description 4
230000033001 locomotion Effects 0.000 description 4
210000004688 microtubule Anatomy 0.000 description 4
238000003801 milling Methods 0.000 description 4
239000002159 nanocrystal Substances 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
210000001258 synovial membrane Anatomy 0.000 description 4
201000000596 systemic lupus erythematosus Diseases 0.000 description 4
229930182986 10-Deacetyltaxol Natural products 0.000 description 3
206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
208000006820 Arthralgia Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 3
102000000503 Collagen Type II Human genes 0.000 description 3
108010041390 Collagen Type II Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
208000003250 Mixed connective tissue disease Diseases 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
208000007641 Pinealoma Diseases 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010038848 Retinal detachment Diseases 0.000 description 3
206010039710 Scleroderma Diseases 0.000 description 3
208000021386 Sjogren Syndrome Diseases 0.000 description 3
201000009594 Systemic Scleroderma Diseases 0.000 description 3
206010042953 Systemic sclerosis Diseases 0.000 description 3
239000004809 Teflon Substances 0.000 description 3
229920006362 Teflon® Polymers 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000033115 angiogenesis Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
238000003556 assay Methods 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
229920002301 cellulose acetate Polymers 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003086 colorant Substances 0.000 description 3
210000001520 comb Anatomy 0.000 description 3
210000002808 connective tissue Anatomy 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
230000008021 deposition Effects 0.000 description 3
229920000359 diblock copolymer Polymers 0.000 description 3
230000005750 disease progression Effects 0.000 description 3
239000000975 dye Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920002643 polyglutamic acid Polymers 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
238000009597 pregnancy test Methods 0.000 description 3
230000004264 retinal detachment Effects 0.000 description 3
230000002207 retinal effect Effects 0.000 description 3
201000000306 sarcoidosis Diseases 0.000 description 3
231100000241 scar Toxicity 0.000 description 3
210000004872 soft tissue Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000001179 synovial fluid Anatomy 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
229940063683 taxotere Drugs 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
ADDGUHVEJPNWQZ-GJKIWTKTSA-N 10-deacetyltaxol b Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 ADDGUHVEJPNWQZ-GJKIWTKTSA-N 0.000 description 2
IHVCSECZNFZVKP-XOVTVWCYSA-N 2'-acetyltaxol Chemical compound N([C@H]([C@@H](OC(=O)C)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 IHVCSECZNFZVKP-XOVTVWCYSA-N 0.000 description 2
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010003571 Astrocytoma Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
206010011026 Corneal lesion Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
206010014967 Ependymoma Diseases 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
229920000855 Fucoidan Polymers 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
229920001503 Glucan Polymers 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010022773 Intracranial pressure increased Diseases 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
206010038933 Retinopathy of prematurity Diseases 0.000 description 2
238000011579 SCID mouse model Methods 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
102100023118 Transcription factor JunD Human genes 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
239000003513 alkali Substances 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
150000001336 alkenes Chemical class 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
125000004103 aminoalkyl group Chemical group 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
229920000617 arabinoxylan Polymers 0.000 description 2
150000004783 arabinoxylans Chemical class 0.000 description 2
125000003435 aroyl group Chemical group 0.000 description 2
230000002917 arthritic effect Effects 0.000 description 2
239000008228 bacteriostatic water for injection Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
238000005266 casting Methods 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000035602 clotting Effects 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000011082 depyrogenation Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
230000007560 devascularization Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000009266 disease activity Effects 0.000 description 2
239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
229940096919 glycogen Drugs 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
238000011597 hartley guinea pig Methods 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000005865 ionizing radiation Effects 0.000 description 2
210000000281 joint capsule Anatomy 0.000 description 2
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000004973 liquid crystal related substance Substances 0.000 description 2
238000007449 liver function test Methods 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002483 medication Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
125000003566 oxetanyl group Chemical group 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
239000001814 pectin Substances 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
230000000649 photocoagulation Effects 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000011886 postmortem examination Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
208000032253 retinal ischemia Diseases 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
239000004334 sorbic acid Substances 0.000 description 2
235000010199 sorbic acid Nutrition 0.000 description 2
229940075582 sorbic acid Drugs 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000008229 sterile water for irrigation Substances 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
125000002456 taxol group Chemical group 0.000 description 2
SKJSIVQEPKBFTJ-HUWILPJBSA-N taxusin Chemical compound C1[C@@H](C2(C)C)C[C@H](OC(C)=O)C(C)=C2[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@]2(C)CC[C@H](OC(=O)C)C(=C)[C@@H]12 SKJSIVQEPKBFTJ-HUWILPJBSA-N 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
230000008719 thickening Effects 0.000 description 2
230000008467 tissue growth Effects 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
210000001585 trabecular meshwork Anatomy 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
229960004355 vindesine Drugs 0.000 description 2
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
NMDYYWFGPIMTKO-KLCPSUAYSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-KLCPSUAYSA-N 0.000 description 2
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
229960002066 vinorelbine Drugs 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
230000004393 visual impairment Effects 0.000 description 2
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
HYJVYOWKYPNSTK-UONOGXRCSA-N (2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoic acid Chemical compound N([C@H]([C@@H](O)C(O)=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 HYJVYOWKYPNSTK-UONOGXRCSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
FNZPZCTVRVPPAB-YZSQHPIKSA-N 14beta-Hydroxy-10-deacetylbaccatin III Chemical class O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)[C@H](O)[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 FNZPZCTVRVPPAB-YZSQHPIKSA-N 0.000 description 1
WQUSBTYBTBXULJ-YUHJQDCISA-N 2',7-diacetyltaxol Chemical compound N([C@H]([C@@H](OC(=O)C)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](OC(C)=O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 WQUSBTYBTBXULJ-YUHJQDCISA-N 0.000 description 1
RBNOJYDPFALIQZ-LAVNIZMLSA-N 2'-succinyltaxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](OC(=O)CCC(O)=O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RBNOJYDPFALIQZ-LAVNIZMLSA-N 0.000 description 1
IRPGOXJVTQTAAN-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanal Chemical compound FC(F)(F)C(F)(F)C=O IRPGOXJVTQTAAN-UHFFFAOYSA-N 0.000 description 1
UKTNDLHXQNQKBH-UHFFFAOYSA-N 2,3-dihydro-1h-indole;1h-indole Chemical class C1=CC=C2NCCC2=C1.C1=CC=C2NC=CC2=C1 UKTNDLHXQNQKBH-UHFFFAOYSA-N 0.000 description 1
239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
HOJZAHQWDXAPDJ-UHFFFAOYSA-N 3-anilino-2-hydroxypropanoic acid Chemical group OC(=O)C(O)CNC1=CC=CC=C1 HOJZAHQWDXAPDJ-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
QHVFIEKTXYELRR-XOVTVWCYSA-N 7-acetyltaxol Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC(=O)C)C(=O)C1=CC=CC=C1 QHVFIEKTXYELRR-XOVTVWCYSA-N 0.000 description 1
KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
YWLXLRUDGLRYDR-LUPIKGFISA-N 7-epi-10-deacetylbaccatin iii Chemical group O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-LUPIKGFISA-N 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
KLZUFWVZNOTSEM-UHFFFAOYSA-K Aluminum fluoride Inorganic materials F[Al](F)F KLZUFWVZNOTSEM-UHFFFAOYSA-K 0.000 description 1
206010003226 Arteriovenous fistula Diseases 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
235000016068 Berberis vulgaris Nutrition 0.000 description 1
241000335053 Beta vulgaris Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
JQIPMLOMQMJUPJ-UHFFFAOYSA-N Brevifoliol Natural products CC(=O)OC1C2(C)C(OC(=O)C)CC(O)C(=C)C2CC2C(C(C)(C)O)C(O)C(C)=C2C1OC(=O)C1=CC=CC=C1 JQIPMLOMQMJUPJ-UHFFFAOYSA-N 0.000 description 1
240000004160 Capsicum annuum Species 0.000 description 1
235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 1
208000009043 Chemical Burns Diseases 0.000 description 1
208000004378 Choroid plexus papilloma Diseases 0.000 description 1
206010009137 Chronic sinusitis Diseases 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
208000005812 Colloid Cysts Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
241000766026 Coregonus nasus Species 0.000 description 1
206010061788 Corneal infection Diseases 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
244000163122 Curcuma domestica Species 0.000 description 1
235000003392 Curcuma domestica Nutrition 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
239000004287 Dehydroacetic acid Substances 0.000 description 1
208000001154 Dermoid Cyst Diseases 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
208000010305 Epidermal Cyst Diseases 0.000 description 1
206010015084 Episcleritis Diseases 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000283086 Equidae Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
101150021185 FGF gene Proteins 0.000 description 1
208000028387 Felty syndrome Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
208000033694 Generalised erythema Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
208000005100 Herpetic Keratitis Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
206010023203 Joint destruction Diseases 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
230000027311 M phase Effects 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
101710151472 Neuroendocrine convertase 1 Proteins 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
241000243985 Onchocerca volvulus Species 0.000 description 1
206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000037064 Papilloma of choroid plexus Diseases 0.000 description 1
208000000450 Pelvic Pain Diseases 0.000 description 1
206010034650 Peritoneal adhesions Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
206010050487 Pinealoblastoma Diseases 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
206010060932 Postoperative adhesion Diseases 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000002392 Rheumatic Nodule Diseases 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
208000001662 Subependymal Glioma Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
241001678487 Taxomyces andreanae Species 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
MHGVSUAAUXQULX-UHFFFAOYSA-N Vinepidine Natural products CCC1CC2CN(CCC3C(=Nc4ccccc34)C(C2)(C(=O)OC)c5cc6c(cc5OC)N(C=O)C7C(O)(C(OC(=O)C)C8(CC)C=CCN9CCC67C89)C(=O)OC)C1 MHGVSUAAUXQULX-UHFFFAOYSA-N 0.000 description 1
208000034698 Vitreous haemorrhage Diseases 0.000 description 1
FVMMMIQAHYVARA-UHFFFAOYSA-N Yunantaxusin Natural products CC(=O)OCC1(O)C(CC(OC(=O)C)C2(C)C(OC(=O)C)C(OC(=O)c3ccccc3)C4=C(C)C(O)CC4(C(O)C12)C(C)(C)O)OC(=O)C FVMMMIQAHYVARA-UHFFFAOYSA-N 0.000 description 1
VWGCDYGRSUJYGJ-GPOPEEISSA-N [(2s,4r,5r,5as,6s,8s,9ar,10as)-5,6-diacetyloxy-2,8-dihydroxy-10a-(2-hydroxypropan-2-yl)-3,5a-dimethyl-9-methylidene-2,4,5,6,7,8,9a,10-octahydro-1h-benzo[g]azulen-4-yl] benzoate Chemical compound O([C@@H]1C2=C(C)[C@@H](O)C[C@]2(C[C@@H]2C(=C)[C@@H](O)C[C@@H]([C@]2([C@H]1OC(C)=O)C)OC(=O)C)C(C)(C)O)C(=O)C1=CC=CC=C1 VWGCDYGRSUJYGJ-GPOPEEISSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229920001284 acidic polysaccharide Polymers 0.000 description 1
150000004805 acidic polysaccharides Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
206010002224 anaplastic astrocytoma Diseases 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
210000001264 anterior cruciate ligament Anatomy 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940124347 antiarthritic drug Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
210000000544 articulatio talocruralis Anatomy 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
229930014667 baccatin III Natural products 0.000 description 1
150000004200 baccatin III derivatives Chemical group 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
201000007917 background diabetic retinopathy Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical class [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
235000013734 beta-carotene Nutrition 0.000 description 1
239000011648 beta-carotene Substances 0.000 description 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
229960002747 betacarotene Drugs 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
229940077187 bismuth tribromophenate Drugs 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
238000002725 brachytherapy Methods 0.000 description 1
230000001680 brushing effect Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
239000001511 capsicum annuum Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
235000012730 carminic acid Nutrition 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
201000005667 central retinal vein occlusion Diseases 0.000 description 1
DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 1
230000009920 chelation Effects 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
208000027157 chronic rhinosinusitis Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
239000012611 container material Substances 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
208000006111 contracture Diseases 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
239000011243 crosslinked material Substances 0.000 description 1
235000003373 curcuma longa Nutrition 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
230000034994 death Effects 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
235000019258 dehydroacetic acid Nutrition 0.000 description 1
229940061632 dehydroacetic acid Drugs 0.000 description 1
JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
HQWKKEIVHQXCPI-UHFFFAOYSA-L disodium;phthalate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C([O-])=O HQWKKEIVHQXCPI-UHFFFAOYSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
150000004141 diterpene derivatives Chemical class 0.000 description 1
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000010894 electron beam technology Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000012976 endoscopic surgical procedure Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
208000017338 epidermoid cysts Diseases 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012632 extractable Substances 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
201000008361 ganglioneuroma Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
229940100242 glycol stearate Drugs 0.000 description 1
235000013761 grape skin extract Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000011554 guinea pig model Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
229940049494 hyaluronic acid 20 mg Drugs 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
201000001371 inclusion conjunctivitis Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
229950003188 isovaleryl diethylamide Drugs 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
239000008263 liquid aerosol Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000005004 lymphoid follicle Anatomy 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
208000010943 meningeal sarcoma Diseases 0.000 description 1
201000007468 meninges hemangiopericytoma Diseases 0.000 description 1
201000003776 meninges sarcoma Diseases 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000004057 myxopapillary ependymoma Diseases 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229910052756 noble gas Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000002042 onchocerciasis Diseases 0.000 description 1
238000002355 open surgical procedure Methods 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000003349 osteoarthritic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000000466 oxiranyl group Chemical group 0.000 description 1
238000002640 oxygen therapy Methods 0.000 description 1
RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000000505 parietal peritoneum Anatomy 0.000 description 1
229940119519 peg-32 stearate Drugs 0.000 description 1
229940119517 peg-6 stearate Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000005043 peripheral vision Effects 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
201000003113 pineoblastoma Diseases 0.000 description 1
206010035059 pineocytoma Diseases 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
229920000059 polyethylene glycol stearate Polymers 0.000 description 1
229940048845 polyglyceryl-3 diisostearate Drugs 0.000 description 1
229940104257 polyglyceryl-6-dioleate Drugs 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000002516 postimmunization Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000001179 pupillary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000004233 retinal vasculature Effects 0.000 description 1
208000004644 retinal vein occlusion Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000005201 scrubbing Methods 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
238000010008 shearing Methods 0.000 description 1
210000002107 sheath cell Anatomy 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000008275 solid aerosol Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229940094938 stannous 2-ethylhexanoate Drugs 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
231100000456 subacute toxicity Toxicity 0.000 description 1
210000005065 subchondral bone plate Anatomy 0.000 description 1
208000030819 subependymoma Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003441 thioacyl group Chemical group 0.000 description 1
125000005309 thioalkoxy group Chemical group 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
230000003868 tissue accumulation Effects 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
230000005758 transcription activity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
SAOHCOFTVLEOCB-UHFFFAOYSA-K tris(2,4,6-tribromophenoxy)bismuthane Chemical compound [Bi+3].[O-]C1=C(Br)C=C(Br)C=C1Br.[O-]C1=C(Br)C=C(Br)C=C1Br.[O-]C1=C(Br)C=C(Br)C=C1Br SAOHCOFTVLEOCB-UHFFFAOYSA-K 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
235000013976 turmeric Nutrition 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
206010046459 urethral obstruction Diseases 0.000 description 1
208000014001 urinary system disease Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000013022 venting Methods 0.000 description 1
229960005212 vindesine sulfate Drugs 0.000 description 1
KLFUUCHXSFIPMH-YBFGSCICSA-N vinepidine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 KLFUUCHXSFIPMH-YBFGSCICSA-N 0.000 description 1
229950001270 vinepidine Drugs 0.000 description 1
229960000922 vinflunine Drugs 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
229910001928 zirconium oxide Inorganic materials 0.000 description 1
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1